ArticleFrontiers in cardiovascular medicine2026
Effect of bucladesine calcium combined with metoprolol on heart rate variability and cardiac function prognosis in heart failure patients with chronic arrhythmias.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) with chronic arrhythmias is associated with autonomic dysfunction and poor outcomes. Heart rate variability (HRV) reflects autonomic dysfunction and predicts outcomes in HF. This study investigated whether adding bucladesine calcium to metoprolol improves HRV and cardiac function compared with metoprolol alone. Methods: This single-center retrospective observational study included 87 patients with HF and chronic arrhythmia treated between January 2023 and April 2024. Patients received metoprolol tartrate alone (control group, Results: Baseline characteristics were comparable between groups. The combination group showed significantly greater improvements in ΔSDNN [mean difference 13.63 ms, 95% CI (4.17, 23.09), Conclusion: Adding bucladesine calcium to metoprolol was associated with greater improvements in HRV time-domain parameters and LVEF, though effects were attenuated after covariate adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.